Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,500 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04788472 | Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL | completed | Phase 2 | 28 | Zhejiang UniversityOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT02927964 | TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma | completed | Phase 1 / Phase 2 | 21 | Robert LowskyOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT02692248 |
| Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT |
| completed |
| Phase 2 |
| 64 |
| Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER |
| 1 |
| Oct 10, 2024 |
| clinicaltrials |
| NCT00747123 | A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma | completed | Phase 2 | 30 | CelgeneINDUSTRY | 1 | Oct 3, 2024 | clinicaltrials |
| NCT02375555 | Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM | completed | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03788291 | Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma | completed | Phase 2 | 39 | University of RochesterOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT02532257 | Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma | completed | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT01243190 | Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | completed | Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01827137 | WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 20 | Sellas Life Sciences GroupINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02633059 | Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Mayo ClinicOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05199337 | Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis | completed | Phase 1 / Phase 2 | 18 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT05557110 | Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL | completed | Phase 2 | 35 | Chen SuningOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03267888 | Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Emory UniversityOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT02633137 | Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma | completed | Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT04847050 | A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2024 | clinicaltrials |
| NCT02157181 | Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab | completed | Phase 2 | 89 | Jurgen BarthOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04605666 | CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies | completed | Phase 2 | 77 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT01199575 | Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 30 | University of California, San DiegoOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT01183949 | Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | completed | Phase 1 / Phase 2 | 18 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02507336 | Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 | completed | Phase 2 | 2 | University of MiamiOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06454266 | First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen) | completed | Phase 2 | 22 | Ningbo No. 1 HospitalOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT01472562 | Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma | completed | Phase 2 | 38 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT02654990 | Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma(PANORAMA_3) | completed | Phase 2 | 248 | pharmaand GmbHINDUSTRY | 22 | Jul 12, 2024 | clinicaltrials |
| NCT03439293 | A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) | completed | Phase 2 | 61 | TakedaINDUSTRY | 6 | Jul 3, 2024 | clinicaltrials |
| NCT04379817 | Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients(SCARLET) | completed | Phase 2 | 23 | Jules Bordet InstituteOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma(LYMRIT-37-01) | completed | Phase 1 / Phase 2 | 191 | Nordic NanovectorINDUSTRY | 24 | Jun 21, 2024 | clinicaltrials |
| NCT03194867 | Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | completed | Phase 1 / Phase 2 | 109 | SanofiINDUSTRY | 10 | Jun 14, 2024 | clinicaltrials |
| NCT01283997 | Prevention of Treatment Induced Neuropathy in Multiple Myeloma | completed | Phase 2 | 79 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT02564744 | Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL | completed | Phase 2 | 100 | Debiopharm International SAINDUSTRY | 9 | Jun 12, 2024 | clinicaltrials |
| NCT02199184 | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT02348216 | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma(ZUMA-1) | completed | Phase 1 / Phase 2 | 307 | Kite, A Gilead CompanyINDUSTRY | 6 | Jun 4, 2024 | clinicaltrials |
| NCT03430011 | Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma(EVOLVE) | completed | Phase 1 / Phase 2 | 165 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | May 24, 2024 | clinicaltrials |
| NCT03184194 | Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide | completed | Phase 2 | 62 | Amsterdam UMC, location VUmcOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT04164368 | Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients | completed | Phase 2 | 67 | Fudan UniversityOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT04438005 | A Study of ICP-022 in Patients With R/R DLBCL(DLBCL) | completed | Phase 2 | 3 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | May 13, 2024 | clinicaltrials |
| NCT02728102 | Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) | completed | Phase 2 | 203 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | May 7, 2024 | clinicaltrials |
| NCT01597219 | Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers(UK-Haplo) | completed | Phase 2 | 77 | University College, LondonOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT01063907 | A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 95 | Kyowa Kirin Co., Ltd.INDUSTRY | 3 | Apr 25, 2024 | clinicaltrials |
| NCT02445248 | Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients(JULIET) | completed | Phase 2 | 115 | Novartis PharmaceuticalsINDUSTRY | 10 | Apr 18, 2024 | clinicaltrials |
| NCT03797456 | A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) | completed | Phase 2 | 111 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Apr 18, 2024 | clinicaltrials |
| NCT02100423 | Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 35 | Paolo Caimi, MDOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT00799513 | Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma(RV-NHL-PI351) | completed | Phase 2 | 48 | IRCCS San RaffaeleOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03848845 | Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM 4) | completed | Phase 1 / Phase 2 | 41 | GlaxoSmithKlineINDUSTRY | 4 | Apr 9, 2024 | clinicaltrials |
| NCT03310619 | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies(PLATFORM) | completed | Phase 1 / Phase 2 | 62 | CelgeneINDUSTRY | 1 | Apr 4, 2024 | clinicaltrials |
| NCT04028115 | Bone Healing During Ninlaro Exposure(BONE) | completed | Phase 2 | 30 | Thomas LundOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT02812706 | Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients(Islands) | completed | Phase 1 / Phase 2 | 36 | SanofiINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT02891811 | Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy | completed | Phase 2 | 124 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 2 | Mar 29, 2024 | clinicaltrials |
| NCT03450057 | Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment(DARE) | completed | Phase 2 | 38 | Hellenic Society of HematologyOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT01897571 | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | completed | Phase 1 / Phase 2 | 400 | Epizyme, Inc.INDUSTRY | 10 | Mar 26, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 17, 2024source: clinicaltrials